A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: A 12-week study

Archives of Ophthalmology

Volumn 114, Issue 8, 1996, Pages 929-932

  Mishima, Hiromu K ^a,e   Masuda, Kanjiro ^b   Kitazawa, Yoshiaki ^c   Azuma, Ikuo ^d   Araie, Makoto ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c GIFU UNIVERSITY   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

^e HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; TIMOLOL;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; BLEPHARITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PRURITUS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; VISUAL IMPAIRMENT;

EID: 0029739619     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.1996.01100140137004     Document Type: Article

References (21)

1. Stjernschantz J, Resul B. Phenyl-substituted prostaglandin analogues for glaucoma treatment. Drugs Future. 1992;17:691-701.
2. Resul B, Stjernschantz J, No K, et al. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J Med Chem. 1993;36:243-248.
3. 2α analogue. In: Samuelsson B, Ramwell PW, Paoletti R, Folco G, Gramström E, Nicosia S, eds. Advances in Prostaglandin, Thromboxane and Leukotriene Research. New York, NY: Raven Press; 1995;23:513-518.
4. Aim A. Villumsen J, Tornquist P, et al. Intraocular pressure reducing effect of PhXA41 in patients with increased eye pressure: a one-month study. Ophthalmology. 1993;100:1312-1317.
5. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
6. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41, in ocular hypertension: comparison of dose regimens. Ophthalmology. 1993;100:1305-1311.
7. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993; 100:1297-1304.
8. 2α analogue (PhXA41): an in-hospital, placebo controlled study. Arch Ophthalmol. 1993;111:657-661.
9. 2α-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol. 1993;37:259-269.
10. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol. 1993;37:270-274.
11. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily causes a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12-16.
12. Sherwood MB, Migdal CS, Hitchings RS, et al. Initial treatment of glaucoma: surgery or medications. Surv Ophthalmol. 1993;37:293-305.
13. 2α in the human eye. Sraefes Arch Clin Exp Ophthalmol. 1985;222:139-141.
14. 2α-isopropyl ester eye drops: effects in normal human eyes. Br J Ophthalmol. 1989;73:419-426.
15. 2α-isopropyl ester eye drops: effect on intraocular pressure in open-angle glaucoma. Br J Ophthalmol. 1989; 73:975-979.
16. 2α-isopropyl ester applied in multiple doses in ocular hyper-tensive and glaucoma patients. Ophthalmology. 1989;96:1329-1337.
17. 2α on intraocular pressure in normotensive human subjects. Invest Ophthalmol Vis Sci. 1988; 29:1474-1477.
18. 2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol. 1988;105:30-34.
19. Alm A, Stjernschantz J, for the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost once daily, evening or morning: a comparison with timolol. Ophthalmology. 1995;102:1743-1752.
20. Watson P, Stjernschantz J, for the Latanoprost Study Group. A six-month randomized, double-masked study comparing latanoprost to timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.
21. Camras CB, for the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked multicenter trial in the United States. Ophthalmology. 1996; 103:138-147.